Pharmacogenetics of Bisphosphonate-associated Osteonecrosis of the Jaw

P L Fung; P Nicoletti; Y Shen; S Porter; S Fedele

doi:10.1016/j.coms.2015.06.005

Pharmacogenetics of Bisphosphonate-associated Osteonecrosis of the Jaw

Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):537-46. doi: 10.1016/j.coms.2015.06.005. Epub 2015 Aug 20.

Authors

P L Fung¹, P Nicoletti², Y Shen³, S Porter¹, S Fedele⁴

Affiliations

¹ UCL Eastman Dental Institute, University College London, 256 Gray's Inn Road, London WC1X 8LD, UK.
² Department of Systems Biology, Irving Cancer Research Center, Columbia University, 1130 St. Nicholas Avenue, New York, NY 10032, USA.
³ Department of Systems Biology, Irving Cancer Research Center, Columbia University, 1130 St. Nicholas Avenue, New York, NY 10032, USA; Department of Biomedical Informatics, Irving Cancer Research Center, Columbia University, 1130 St. Nicholas Avenue, New York, NY 10032, USA.
⁴ UCL Eastman Dental Institute, University College London, 256 Gray's Inn Road, London WC1X 8LD, UK; NIHR Biomedical Research Centre, University College London Hospitals, 149 Tottenham Court Road, London W1T 7DN, UK. Electronic address: [email protected].

PMID: 26299425
DOI: 10.1016/j.coms.2015.06.005

Abstract

Osteonecrosis of the jaws (ONJ) is a potentially severe disorder that develops in a subgroup of individuals who have used bisphosphonate (BP) medications. Several clinical risk factors have been associated with the risk of ONJ development, but evidence is limited and in most instances ONJ remains an unpredictable adverse drug reaction. Interindividual genetic variability can contribute to explaining ONJ development in a subset of BP users and the discovery of relevant associated gene variants could lead to the identification of individuals at higher risk. No genetic variant has been found to be robustly associated with susceptibility to ONJ.

Keywords: Bisphosphonates; Genes; Jaw osteonecrosis; Pharmacogenetics; Pharmacogenomics; Single-nucleotide polymorphisms.

Publication types

Review

MeSH terms

Bisphosphonate-Associated Osteonecrosis of the Jaw / genetics*
Bone Density Conservation Agents / adverse effects*
Diphosphonates / adverse effects*
Humans
Pharmacogenetics*
Risk Factors

Substances

Bone Density Conservation Agents
Diphosphonates